Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BCDA Relative to the S&P 500

BCDA Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the BioCardia, Inc. (NASD:BCDA) seasonal charts above shows that a Buy Date of December 12 and a Sell Date of March 1 has resulted in a geometric average return of 1.08% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 35.76% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow.? CardiAMP? autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an ?off the shelf? cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO?), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

To download BCDA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BCDA